Target-Selected CAR-NK Cells (CD30, CD5, or Mesothelin) for Relapsed/Refractory B2 Thymoma or Thymic Carcinoma
Clinical trial NCT07598955 · RECRUITING
Trial details
- NCT number
- NCT07598955
- Sponsor
- Beijing Biotech
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-02
- Primary completion
- 2027-06-14
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.